In short
Clinical trials are currently underway to investigate the potential of BI 1291583, a new drug being studied for its effects on bronchiectasis and cystic fibrosis bronchiectasis. These trials aim to assess the drug's safety, tolerability, and effectiveness in treating these respiratory conditions. The studies involve various formulations and dosages of BI 1291583, as well as examining how the drug is processed in the body. This article summarizes the key findings from these ongoing clinical trials.
At a glance
- Drug Name
- BI 1291583
- Conditions Studied
- Bronchiectasis, Cystic Fibrosis Bronchiectasis
- Administration
- Oral tablet, once daily
- Trial Durations
- 12 weeks to 1 year
- Primary Outcomes
- Safety, tolerability, time to first pulmonary exacerbation
- Secondary Outcomes
- Rate of pulmonary exacerbations, quality of life measures, lung function (FEV1), neutrophil elastase activity
- Pharmacokinetic Measures
- AUC, Cmax, bioavailability
- Study Designs
- Randomized, double-blind, placebo-controlled, parallel group
What is BI 1291583?
BI 1291583 is a new investigational drug being developed to treat certain respiratory conditions. It is currently undergoing clinical trials to evaluate its safety, effectiveness, and how it behaves in the human body. This medication is not yet approved for general use and is still in the research phase.
What Conditions Does BI 1291583 Treat?
Based on the clinical trials information, BI 1291583 is being studied for the treatment of two main conditions:
- Bronchiectasis: This is a condition where the airways in the lungs become abnormally widened, leading to a build-up of excess mucus. This can cause repeated lung infections and breathing difficulties.
- Cystic Fibrosis Bronchiectasis: This is a specific type of bronchiectasis that occurs in people with cystic fibrosis, a genetic disorder affecting the lungs and other organs.
How Does BI 1291583 Work?
While the exact mechanism of action is not explicitly stated in the provided information, we can infer some details based on the clinical trial data:
- BI 1291583 appears to have an effect on neutrophil elastase (NE) activity in sputum. Neutrophil elastase is an enzyme released by white blood cells that can contribute to inflammation and tissue damage in the lungs. Reducing its activity may help alleviate symptoms in bronchiectasis.
- The drug seems to target the underlying causes of pulmonary exacerbations (flare-ups) in bronchiectasis, potentially reducing their frequency and severity.
- It may also improve lung function, as measured by tests like forced expiratory volume in one second (FEV1), which is the amount of air a person can forcefully exhale in one second.
Clinical Trials and Research
BI 1291583 is currently being studied in several clinical trials:
- Safety and Tolerability Studies: These trials are testing how well the drug is tolerated by healthy volunteers and patients with bronchiectasis, and what side effects it might cause.
- Pharmacokinetic Studies: These investigate how the drug is absorbed, distributed, metabolized, and eliminated by the body.
- Efficacy Studies: Larger trials are examining whether BI 1291583 is effective in treating bronchiectasis, including how it affects exacerbations, quality of life, and lung function.
- Long-term Studies: Some trials are looking at the long-term safety and efficacy of BI 1291583 in patients with bronchiectasis.
How is BI 1291583 Administered?
Based on the clinical trial information, BI 1291583 is administered as follows:
- It is taken orally as a tablet.
- The dosing is typically once daily.
- Different doses are being tested to determine the most effective and safe amount.
- Some studies are investigating how food affects the absorption of the drug.
Potential Side Effects
As BI 1291583 is still in clinical trials, a complete list of side effects is not yet available. The trials are carefully monitoring for any adverse events (unwanted effects) that may occur. These studies will help determine the safety profile of the drug.
Future Prospects
BI 1291583 shows promise as a potential new treatment for bronchiectasis and cystic fibrosis bronchiectasis. If the clinical trials demonstrate that it is safe and effective, it could provide a new option for patients with these conditions. However, it's important to note that the drug is still in the research phase, and more studies are needed before it can be considered for approval by regulatory agencies.